Daily Cardiology Research Analysis
Three impactful cardiology studies span translational discovery and real-world implementation. A proteomics-based investigation identifies S100A8/A9 as a diagnostic biomarker and therapeutic target in fulminant myocarditis; a pragmatic nationwide factorial RCT shows electronic nudges do not increase GDMT uptake in CKD; and circulating miR-15a emerges as a mechanistic biomarker for AAA with in vivo inhibitory effects on aneurysm growth.
Summary
Three impactful cardiology studies span translational discovery and real-world implementation. A proteomics-based investigation identifies S100A8/A9 as a diagnostic biomarker and therapeutic target in fulminant myocarditis; a pragmatic nationwide factorial RCT shows electronic nudges do not increase GDMT uptake in CKD; and circulating miR-15a emerges as a mechanistic biomarker for AAA with in vivo inhibitory effects on aneurysm growth.
Research Themes
- Translational biomarkers and therapeutic targeting in inflammatory cardiac disease
- Real-world implementation trials for cardio-renal guideline therapies
- Mechanistic microRNA biomarkers in aortic disease
Selected Articles
1. MicroRNA-15a-5p mediates abdominal aortic aneurysm progression and serves as a potential diagnostic and prognostic circulating biomarker.
In a discovery cohort (187 AAA vs 190 controls) with two independent validations and two murine models, circulating and tissue miR-15a levels were elevated in AAA and correlated with aneurysm diameter. Functional studies implicated miR-15a in AAA pathogenesis via downregulation of target genes in vascular smooth muscle, and in vivo inhibition reduced aneurysm growth.
Impact: This study identifies a mechanistically implicated, circulating microRNA biomarker for AAA and demonstrates therapeutic modulation in vivo, addressing a major unmet need for noninvasive risk stratification and disease-modifying strategies.
Clinical Implications: miR-15a could enable blood-based AAA detection and risk stratification, aiding surveillance intervals and timing of repair, while miR-15a inhibition suggests a novel disease-modifying approach pending clinical translation.
Key Findings
- Circulating miR-15a was significantly upregulated in AAA versus controls and correlated with aneurysm diameter across three patient cohorts.
- miR-15a was increased in AAA aortic media and in two murine AAA models, supporting cross-species relevance.
- Inhibition of miR-15a in vivo significantly reduced aortic diameter growth at day 7 in murine AAA.
- Target gene analyses in human aortic smooth muscle cells identified downregulated genes consistent with AAA pathology.
Methodological Strengths
- Multi-cohort human validation with both circulating and tissue-level measurements
- Cross-species confirmation and in vivo functional inhibition in murine AAA models
Limitations
- Clinical utility thresholds and prospective biomarker performance for rupture risk were not established
- Heterogeneity of validation cohort sizes and lack of randomized human intervention
Future Directions: Prospective studies to define clinical cutoffs for miR-15a in surveillance and to test miR-15a-targeted therapies in early-phase human trials.
BACKGROUND: MicroRNAs are post transcriptional modulators of gene expression. We explored the diagnostic and prognostic value of circulating microRNAs in abdominal aortic aneurysm (AAA) disease, for which currently no established circulating biomarker is available. METHODS: We profiled the expression of 754 human microRNAs in plasma from 187 patients with AAA and 190 matched non-diseased controls. To validate, we used two additional AAA patient cohorts, looking at circulating and aortic tissue-derived microRNA expression, and their correlation to AAA disease phenotype, as well as two murine AAA models. RESULTS: We show that among 12 differentially expressed microRNAs, miR-15a and -659 are the most significantly up-regulated in AAA, whereas miR-1183 and -192 are the most significantly down-regulat
2. A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients With Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial.
In a nationwide, pragmatic 2×2 factorial RCT in Denmark (22,617 randomized at patient level; 1,540 GP practices randomized), electronic letters nudging patients or their GPs did not increase 6-month uptake of RAS inhibitors or SGLT2 inhibitors compared with usual care.
Impact: High-quality, preregistered, nationwide RCT provides definitive evidence that simple electronic nudges alone are insufficient to close the GDMT implementation gap in CKD, informing health-system design.
Clinical Implications: Implementing guideline therapies for cardio-renal risk reduction likely requires multifaceted strategies beyond electronic letters (e.g., care pathways, pharmacist-led titration, decision support, incentive alignment).
Key Findings
- Patient-directed nudge: 65.1% vs 65.9% filled prescription for RASi/SGLT2i at 6 months (difference −0.79 percentage points; 95% CI −2.03 to 0.45).
- Provider-directed nudge to general practices also did not significantly change uptake versus usual care.
- Nationwide pragmatic 2×2 factorial design with registry-based outcome ascertainment enhances generalizability and internal validity.
Methodological Strengths
- Nationwide pragmatic factorial RCT with dual-level randomization (patient and practice)
- Pre-registered trial using comprehensive administrative registries for outcomes
Limitations
- Intervention intensity limited to single electronic letters; may be insufficient to change prescribing behavior
- Short 6-month follow-up focuses on uptake, not clinical outcomes
Future Directions: Test multifactorial, behaviorally informed implementation bundles (audit/feedback, pharmacist titration, e-prescribing defaults) and evaluate downstream cardio-renal outcomes.
BACKGROUND: Many individuals with chronic kidney disease (CKD) face a considerable but modifiable risk of cardiovascular and renal outcomes because of suboptimal implementation of guideline-directed medical therapy (GDMT). We investigated whether electronic letter-based nudges delivered to individuals with CKD and their general practices could increase GDMT uptake. METHODS: This was a nationwide 2×2 factorial implementation trial with randomization at the patient and general practice level and analyzed at the patient level. All Danish adults with a hospital diagnosis of CKD and access to the official Danish electronic letter system were individually randomized at a 1:1 ratio to usual care (no letter) or to receive an electronic letter-based nudge on GDMT for CKD; general practitioners of individuals with CKD were independently randomized (1:1) to receive no letter or an electronic informational letter on GDMT. Intervention letters were delivered on August 19, 2024. Data were collected through the Danish administrative health registries. The primary end point was a filled prescription of a renin-angiotensin system inhibitor or a sodium-glucose cotransporter 2 inhibitor within 6 months of intervention delivery. RESULTS: A total of 22 617 patients with CKD were randomized to the patient-level intervention, with 11 223 allocated to receive the electronic nudge letter and 11 394 to usual care. Separately, 1540 general practices caring for 28 069 patients with CKD were randomized to the provider-level intervention, with 774 practices (13 959 patients) allocated to the intervention and 766 practices (14 110 patients) to usual care. During follow-up, 7303 (65.1%) allocated to the patient-directed nudge had filled a prescription for a renin-angiotensin system inhibitor or sodium-glucose cotransporter 2 inhibitor compared with 7505 (65.9%) in usual care (difference, -0.79 percentage points [95% CI, -2.03 to 0.45]; CONCLUSIONS: In this nationwide pragmatic, 2×2 factorial implementation trial, electronic letter-based nudges on GDMT delivered to patients with CKD or their general practice did not increase the uptake of a renin-angiotensin system inhibitor or sodium-glucose cotransporter 2 inhibitor as compared with usual care. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06300086.
3. Plasma proteomics identifies S100A8/A9 as a novel biomarker and therapeutic target for fulminant myocarditis.
Across three clinical cohorts with validation and a CVB3-induced mouse model, plasma S100A8/A9 levels strongly associated with fulminant myocarditis severity and adverse outcomes. Pharmacologic blockade of S100A8/A9 (ABR-238901) reduced mortality and improved cardiac function in mice, supporting therapeutic potential.
Impact: Provides a mechanistically grounded biomarker with prognostic value and demonstrates druggability in vivo, opening a translational path for FM where timely diagnosis and effective therapy are lacking.
Clinical Implications: S100A8/A9 measurement may aid early FM diagnosis and risk stratification; targeted inhibition could represent a future adjunctive anti-inflammatory therapy pending human trials.
Key Findings
- Plasma S100A8/A9 levels correlated with FM severity and adverse outcomes (cardiac death, transplant, HF/myocarditis hospitalization).
- Myocardial S100A8/A9 was elevated in CVB3-induced FM mice, mirroring plasma findings.
- ABR-238901 inhibition of S100A8/A9 reduced mortality and improved cardiac function by attenuating acute inflammation.
Methodological Strengths
- Comprehensive proteomics across multiple clinical cohorts with independent validation
- Translational in vivo testing of a targeted inhibitor in a relevant FM model
Limitations
- Exact clinical cohort sizes and selection criteria not detailed in abstract; potential spectrum bias
- Therapeutic efficacy demonstrated only in mice; no human interventional data
Future Directions: Prospective clinical validation of S100A8/A9 thresholds and early-phase trials of S100A8/A9 inhibitors in FM.
INTRODUCTION: Fulminant myocarditis (FM) is a lethal inflammatory myocardial disease characterized by rapid progression and poor prognosis. Investigating plasma proteins linked to FM may elucidate underlying pathological mechanisms, identify novel biomarkers for early detection in high-risk populations, and advance the development of targeted therapeutic strategies. OBJECTIVES: This study aimed to investigate the proteomic profiles of FM patients and identify potential biomarkers and therapeutic targets, focusing on S100A8/S100A9. METHODS: We conducted a comprehensive proteomic analysis of an extensive plasma sample collection derived from FM patients across three clinical cohorts. Our approach included screening for proteins correlated with cardiac dysfunction and disease severity. Key findings were validated in an independent cohort. In parallel, we employed a CVB3-induced FM mouse model to evaluate the expression of these biomarkers in myocardial tissue and assessed the effects of targeted interventions. Specifically, we investigated the therapeutic impacts of blocking the S100A8/A9 heterodimer using the inhibitor ABR-238901. RESULTS: The analysis revealed significant innate immune activation and severe metabolic disturbances in FM patients. Through proteomic profiling and correlation analysis, proteins S100A8 and S100A9 emerged as significant biomarkers linked to cardiac dysfunction and FM severity. S100A8/A9 heterodimer was validated as a crucial diagnostic marker for FM, with elevated plasma levels correlating with increased rates of cardiac death, heart transplantation, and hospitalizations due to heart failure or myocarditis. In CVB3-induced FM mouse models, myocardial tissues showed increased levels of S100A8 and S100A9. Treatment with ABR-238901 significantly reduced mortality by alleviating acute inflammation and improving cardiac function. CONCLUSION: S100A8/A9 emerged as an essential biomarker and a promising therapeutic target for FM. These findings offer new insights into FM diagnosis and suggest potential intervention strategies. These results pave the way for further research to validate the clinical application of S100A8/A9-targeted therapies, potentially improving outcomes for patients suffering from this severe cardiac condition. TRIAL REGISTRATION: ClinicalTrials.gov NCT03268642.